At our clinic, we consider CVVHDF-CAH (oXiris®) for all hemodynamically unstable (oliguric) critically ill patients who show signs of an uncontrolled inflammatory syndrome (C-reactive protein > 40 mg/ml and procalcitonin > 0.5 ng/ml) in combination with reduced GFR. This evidence concerns the gene CRP and congenital adrenal hyperplasia.